NEW YORK, March 02, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc. securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.
To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Want to cut your energy bills? Here’s how five experts are doing it
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 



